Shopping Cart
Remove All
Your shopping cart is currently empty
Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $228 | In Stock | In Stock | |
| 5 mg | $589 | In Stock | In Stock | |
| 10 mg | $967 | - | In Stock | |
| 25 mg | $1,430 | - | In Stock | |
| 50 mg | $1,930 | - | In Stock |
| Description | Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site. Injections of Concizumab increase thrombin in blood, thereby preventing and treating hemophilia. |
| In vitro | In a concentration-dependent manner, Concizumab increases the peak value of thrombin [1]. |
| In vivo | In cynomolgus monkeys, Concizumab (i.v./s.c.) blocked the interaction between TFPI and FXa active site [2]. |
| Synonyms | NN 7415, mAb 2021 |
| Molecular Weight | 145.76 kDa |
| Cas No. | 1312299-39-0 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.